Seegene submits SARS-CoV-2, flu A/B, RSV assay for EUA

Create PDF

March 2, 2021—Seegene announced it has submitted its Allplex SARS-CoV-2/FluA/FluB/RSV Assay to the FDA for emergency use authorization.

The assay is a real-time RT-PCR assay that can simultaneously detect and differentiate eight target genes including flu A, flu B, RSV A/B and three different target genes of COVID-19—S, RdRP, and N genes. The assay also includes dual targets for internal control in the same reaction tube.